BioSpace News Archive

Versant Ventures and Westlake Village BioPartners announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases.

The Annual General Meeting of BioInvent International AB resolved to elect Vincent Ossipow as new Board member and to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer and Bernd Seizinger.

Amarin Corporation plc, announced that Joseph T. Kennedy has informed the board of directors of his decision to retire as executive vice president, general counsel and strategic initiatives.

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of the stroke caused by carotid artery disease, announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced that it will host a conference call to discuss its first quarter 2021 financial results on Monday, May 10th, 2021 at 7:30 a.m. Pacific Time.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021 . First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion . First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.

West Pharmaceutical Services, Inc. announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance.

Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced the opening of a new production center in the Dominican Republic by its manufacturing partner Jabil Inc.